Published Date: 24-Nov-2021
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Veterinary Dermatology Drugs Market, published by KBV research, The Global Veterinary Dermatology Drugs Market size is expected to reach $13.6 billion by 2027, rising at a market growth of 8.2% CAGR during the forecast period.
In 2020, the livestock animal segment acquired the significant revenue share. In addition, the segment is further segregated into cattle and others. Factors such as massive demand for animal protein and the occurrence of parasitic diseases in livestock animals are responsible for the growth of this segment. The cattle segment is likely to showcase the fastest growth rate during the forecast period.
In 2020, the oral segment garnered the maximum revenue share in the veterinary dermatology drugs market. Factors such as the massive availability of oral drugs in the form of tablets, feed additives, and pills are responsible for the growth of this segment. Moreover, market players are taking many initiatives associated with the oral route of administration which is likely to propel the growth of this segment.
APAC region is likely to show a promising growth rate during the forecast period. Factors like an increase in demand for veterinary dermatology drugs and increased awareness about the availability of these products in developing countries like India and China are expected to boost the regional market during the forecasting period. Moreover, as APAC region has the presence of many manufacturing units of key market players like Elanco, which would further propel the growth of the regional market.
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck Group, Elanco Animal Health, Inc., Zoetis, Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Vetoquinol SA (Soparfin SCA), Virbac, Bioibérica, S.A.U., Bimeda, Inc., and Ceva Santé Animale.
By Route of Administration
By Distribution Channel
By Drug Indication
By Animal Type
Unique Offerings from KBV Research